Approved indications: Xpovio is FDA‑approved for adults with multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, in combination with dexamethasone after at least four prior therapies and disease refractory to multiple prior myeloma drugs, and as a single agent for adults with relapsed or refractory diffuse large B‑cell lymphoma (including DLBCL arising from follicular lymphoma) after at least two prior lines of systemic therapy.

Off‑label uses: Clinicians may consider Xpovio in other later‑line combination regimens for relapsed or refractory multiple myeloma or lymphoma, most often in clinical trials or specialized centers; evidence for these off‑label uses typically comes from small studies and early‑phase or investigator‑initiated trials, so the strength of evidence is moderate to limited compared with its labeled indications.

Efficacy expectations in multiple myeloma: When added to bortezomib and dexamethasone in previously treated myeloma, Xpovio improves the chance of tumor shrinkage and prolongs time before the disease worsens compared with bortezomib and dexamethasone alone, with many patients who respond showing improvement within the first 1–3 treatment cycles (weeks to a few months).

Efficacy expectations in heavily pretreated myeloma and DLBCL: In patients with very heavily pretreated multiple myeloma or relapsed/refractory DLBCL, response rates are more modest (roughly about one‑quarter to one‑third of patients respond), but responses can be meaningful and may last several months or longer in those who benefit.

Comparison to other drugs: Unlike many other myeloma and lymphoma drugs, Xpovio works by inhibiting nuclear export (XPO1) rather than targeting proteasomes, immunomodulatory pathways, or CD38, so it is generally used after standard treatments have failed; it can be effective when other drug classes have stopped working, but it also tends to cause more gastrointestinal symptoms, low blood counts, and fatigue than some alternatives, requiring close monitoring and dose adjustments.

Typical adult dosing: For multiple myeloma in combination with bortezomib and dexamethasone (XVd), the usual Xpovio dose is 100 mg taken by mouth once weekly; for multiple myeloma in combination with dexamethasone alone (Xd), the usual dose is 80 mg taken by mouth on Days 1 and 3 of each week; for relapsed or refractory DLBCL, the usual dose is 60 mg taken by mouth on Days 1 and 3 of each week.

How to take the medicine: Xpovio tablets are swallowed whole with water, without crushing, chewing, or splitting, usually at about the same time of day, with or without food (many patients take it with a light meal and prescribed anti‑nausea medicine to reduce stomach upset); it is important to drink plenty of fluids and maintain adequate calories during treatment.

Special dosing instructions: Doses are often adjusted or temporarily held for side effects such as low blood counts, severe nausea or vomiting, diarrhea, weight loss, or low sodium, and patients with severe liver impairment may start at a reduced dose; prescribers commonly give anti‑nausea medication before and during therapy and schedule frequent labs early in treatment to guide dose changes.

Missed dose guidance: If a dose is missed, the general advice is to skip the missed dose and take the next dose at the regularly scheduled day and time without doubling up, and if vomiting occurs after a dose, do not take an extra dose that day but wait until the next scheduled dose; patients should confirm exact instructions with their treating team.

Overdose: There is no specific antidote for Xpovio overdose; if too many tablets are taken, or if there is concern for overdose, emergency medical care or poison control should be contacted immediately so that supportive care, monitoring of blood counts and electrolytes, and management of symptoms can be provided.

Common side effects: Frequently reported effects include fatigue or weakness, nausea and vomiting, diarrhea or constipation, decreased appetite and weight loss, low blood counts (especially low platelets, anemia, and low white cells), low sodium levels, and infections such as upper respiratory infections; these often begin in the first few weeks of treatment and can range from mild to severe but are often managed with anti‑nausea medicines, fluids, nutritional support, growth factors, and dose changes.

Serious or rare adverse effects: Xpovio can cause severe thrombocytopenia with bleeding, serious infections and neutropenia, profound hyponatremia (low sodium) leading to confusion, seizures, or falls, severe dehydration from vomiting or diarrhea, neurologic symptoms such as dizziness, confusion, or altered mental status, and eye problems including cataracts or vision changes, all of which require prompt medical evaluation and often urgent treatment or dose interruption.

Warnings and precautions (pregnancy, breastfeeding, organ function, age): Xpovio can harm an unborn baby; pregnancy testing is recommended before starting in people who can become pregnant, and effective contraception is advised during treatment and for at least 1 week after the last dose, while breastfeeding should be avoided during treatment and for 1 week after the last dose; it is not approved for children under 18 years. Patients with pre‑existing low blood counts, dehydration, poor nutritional status, or significant liver or kidney problems need especially close monitoring and may require lower starting doses or more frequent lab checks, and older or frail adults may be more sensitive to side effects.

Overall safety profile compared with other therapies: Compared with some other myeloma and lymphoma drugs, Xpovio tends to cause more nausea, appetite loss, weight loss, fatigue, and hyponatremia, and often needs proactive supportive care and dose modifications, but it has relatively few classic drug–drug interactions and offers a different treatment option when other regimens are no longer effective.

Side‑effect monitoring and reporting: Patients are usually monitored with regular blood tests (for blood counts, electrolytes including sodium, and kidney and liver function), weight and hydration checks, and assessments for neurologic symptoms and vision changes; any unusual or severe symptoms should be reported quickly to the treating team. Side effects can also be reported directly to the FDA MedWatch program (online or by phone) or to the drug manufacturer, where ongoing safety information and updates about Xpovio are maintained.

Drug and supplement interactions: Based on clinical studies, Xpovio has relatively few major pharmacokinetic interactions, and its blood levels are not significantly changed by strong CYP3A inhibitors or inducers, but all prescription drugs, over‑the‑counter medicines, and supplements should still be reviewed by the prescriber. Because Xpovio can inhibit the liver transporter OATP1B3, caution is advised with medicines that depend on this transporter (such as some statins and other specialty drugs), and dose adjustments or closer monitoring may be needed.

Other medicines, foods, and alcohol: Taking Xpovio together with other drugs that lower blood counts, increase bleeding risk (such as anticoagulants) or cause significant nausea and dehydration can increase the chance of side effects, so these combinations require careful monitoring. There are no specific food restrictions, but maintaining good hydration and nutrition is important; alcohol can worsen dizziness, fatigue, and stomach irritation, so limiting or avoiding alcohol is generally recommended.

Precautions and conditions where use may be unsafe: Extra caution is needed in people with very low baseline blood counts, uncontrolled infection, severe liver disease, significant electrolyte abnormalities, poor performance status, or untreated severe nausea, vomiting, or diarrhea, and in these situations the drug may need to be deferred, started at a lower dose, or given with intensive supportive care.

Monitoring needs: Patients typically need regular complete blood counts, electrolyte checks (especially sodium), kidney and liver function tests, and monitoring of weight, fluid status, and nutritional intake, particularly during the first two to three months; clinicians may also monitor neurologic function and vision over time and adjust treatment based on lab trends and symptoms.

Q: What is Xpovio used for?
A: Xpovio is an oral cancer medicine used in adults to treat certain types of relapsed or refractory multiple myeloma (in combination with other drugs) and diffuse large B‑cell lymphoma after other treatments have stopped working.

Q: How long does it take for Xpovio to start working?
A: Many patients who respond begin to see improvement in blood tests or scans within the first one to three treatment cycles (a few weeks to a few months), although some may respond later.

Q: How long will I need to stay on Xpovio?
A: Treatment is usually continued as long as it is controlling the disease and side effects remain manageable, so the duration varies from person to person and is decided based on response and tolerability.

Q: Can I take Xpovio with food and my other medicines?
A: Xpovio can be taken with or without food and is often taken with a light meal and anti‑nausea medicine, but all other prescription drugs, over‑the‑counter medicines, and supplements should be reviewed by your cancer team to check for interactions and overlapping side effects.

Q: What should I do if I vomit after taking a dose?
A: If you vomit after taking Xpovio, you should not take an extra dose that day and should simply take your next scheduled dose on your usual dosing day, and let your care team know so they can adjust anti‑nausea medicines or the dose if needed.

Q: Is Xpovio safe during pregnancy or breastfeeding?
A: Xpovio can harm an unborn baby, so effective birth control is needed during treatment and for at least one week after the last dose, and breastfeeding is not recommended during treatment or for one week after the last dose.

Storage: Keep Xpovio tablets at room temperature (around 68–77°F or 20–25°C), in the original packaging or blister pack to protect from moisture and light, and store them in a dry place away from heat, humidity (like bathrooms), and out of sight and reach of children and pets.

Handling: Swallow tablets whole; do not crush, chew, or split them, and avoid handling broken tablets; if a tablet breaks, wash your hands after touching it and wipe the area with a damp disposable towel.

Disposal: Do not throw leftover tablets in household trash or flush them down the toilet unless specifically instructed; instead, use a community drug take‑back program or ask your pharmacy for take‑back options, or, if none are available, mix tablets (in their blister, if possible) with something unappealing like used coffee grounds or cat litter in a sealed container before discarding in the household trash.